{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:09:51Z","timestamp":1780920591357,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101122","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:15:26Z","timestamp":1769793326000},"page":"101122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment and outcomes of patients with HR+\/HER2\u2212 early breast cancer in a real-world setting in Germany"],"prefix":"10.1016","volume":"47","author":[{"given":"Klaus-Ulrich","family":"D\u00e4\u00dfler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-Oliver","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Korfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Emde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"R\u00f6\u00dfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kruggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Tech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"J\u00e4nicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101122_bib0001","unstructured":"Globocan 2020 [Internet]. Access 19 May 2023. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/20-Breast-fact-sheet.pdf."},{"key":"10.1016\/j.ctarc.2026.101122_bib0002","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s11845-022-02926-x","article-title":"Breast cancer recurrence: factors impacting occurrence and survival","volume":"191","author":"Courtney","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.ctarc.2026.101122_bib0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101122_bib0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.ctarc.2026.101122_bib0006","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101122_bib0007","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database","volume":"25","author":"Hwang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101122_bib0008","series-title":"NCCN Guidelines - Breast Cancer","year":"2023"},{"key":"10.1016\/j.ctarc.2026.101122_bib0009","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/1055-9965.EPI-11-1089","article-title":"Hazard of recurrence among women after primary breast cancer treatment\u2014A 10-year follow-up using data from SEER-Medicare","volume":"21","author":"Cheng","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ctarc.2026.101122_bib0010","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","article-title":"Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101122_bib0011","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-017-4358-6","article-title":"Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: 5-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial","volume":"165","author":"Nitz","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101122_bib0012","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101122_bib0013","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/jpm12030382","article-title":"Feasibility of adjuvant treatment with abemaciclib-real-world data from a large German breast center","volume":"12","author":"Dannehl","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ctarc.2026.101122_bib0014","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0960-9776(23)00135-2","article-title":"P016. Patient characteristics, treatment and long-term outcomes from a real-world population of early breast cancer patients at high risk of recurrence in Scotland","volume":"68","author":"Hall","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.ctarc.2026.101122_bib0015","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2217\/fon-2022-0310","article-title":"A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2\u2212negative early breast cancer","volume":"18","author":"Sheffield","year":"2022","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101122_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"SOFT and TEXT investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal Breast Cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"S3","key":"10.1016\/j.ctarc.2026.101122_bib0017","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/j.annonc.2022.03.093","article-title":"77P A real-world population study in early breast cancer to identify patient characteristics, treatment and outcomes in Scotland","volume":"33","author":"Hall","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101122_bib0018","unstructured":"Verzenios summary of product characteristics. Accessed 21 May 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/verzenios-epar-product-information_en.pdf."},{"key":"10.1016\/j.ctarc.2026.101122_bib0019","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2\u2212negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101122_bib0020","article-title":"Overall survival with abemaciclib in early breast cancer","author":"Johnston","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101122_bib0021","unstructured":"Kisqali summary of product characteristics. Accessed 07 December 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisqali-epar-product-information_en.pdf."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101122_bib0022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422600033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:37:32Z","timestamp":1780918652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422600033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"alternative-id":["S246829422600033X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101122","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and outcomes of patients with HR+\/HER2\u2212 early breast cancer in a real-world setting in Germany","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101122"}}